Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach
JNCI: Journal of the National Cancer Institute · 05.04.2024 · 116 (4) · 539-546
DOI: 10.1093/jnci/djad232 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 15.11.2023. Verfasst von Shirly Grynberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Ameloblastoma, Imidazoles, Oximes. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E mutation is present in approximately 80% of mandible ameloblastomas, and BRAF inhibitors have demonstrated sustained responses in unresectable cases.
Methods
We identified ameloblastoma patients planned for ablative surgery and screened them for BRAF V600E mutation. Neoadjuvant BRAF inhibitors were offered to facilitate jaw preservation surgery. Retrospective data collection encompassed treatment regimens, tolerability, tumor response, and conversion to mandible preservation surgery.
Results
Between 2017 and 2022, a total of 11 patients received dabrafenib (n = 6) or dabrafenib with trametinib (n = 5). The median age was 19 (range = 10-83) years. Median treatment duration was 10 (range = 3-20) months. All (100%) patients achieved a radiological response. Ten (91%) patients successfully converted to mandible preservation surgery with residual tumor enucleation. One patient attained complete radiological response, and surgery was not performed. Among the 10 surgically treated patients, all exhibited a pathological response, with 4 achieving near complete response and 6 partial response. At a median follow-up of 14 (range = 7-37) months after surgery, 1 case of recurrence was observed. Grade 1-2 adverse effects were reported in 8 (73%) patients, with a single case of grade 3 (hepatitis). Dose modification was necessary for 3 patients, and 4 experienced treatment interruptions, while 1 patient permanently discontinued therapy.
Conclusions
Neoadjuvant BRAF inhibition may offer a safe and effective strategy for organ preservation in mandible ameloblastoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ella Lemelbaum Institute of Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, Israel.
- Institue of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
- Sheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.
- Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel.
- Division of Pediatric Hemato-Oncology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
- Department of Cranio-Maxillofacial Surgery, Sheba Medical Center, Tel Hashomer, Israel.
ORCID-Profile: Shirly Grynberg, Marilena Vered, Ronnie Shapira-Frommer, Nethanel Asher, Guy Ben-Betzalel, Ronen Stoff, Yael Steinberg, Ninette Amariglio, Gahl Greenberg, Iris Barshack, Amos Toren, Jacob Schachter, Gadi Abebe Campino
Zitieren
APA
Grynberg, S., Vered, M., Shapira-Frommer, R., Asher, N., Ben-Betzalel, G., Stoff, R., Steinberg, Y., Amariglio, N., Greenberg, G., Barshack, I., Toren, A., Yahalom, R., Schachter, J., Rechavi, G., Hirschhorn, A., & Abebe Campino, G. (2024). Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. JNCI: Journal of the National Cancer Institute, 116(4), 539-546. https://doi.org/10.1093/jnci/djad232
Vancouver
Grynberg S, Vered M, Shapira-Frommer R, Asher N, Ben-Betzalel G, Stoff R, et al. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. JNCI: Journal of the National Cancer Institute. 2024;116(4):539-546. doi:10.1093/jnci/djad232
BibTeX
@article{Grynberg2024,
author = {Grynberg, Shirly and Vered, Marilena and Shapira-Frommer, Ronnie and Asher, Nethanel and Ben-Betzalel, Guy and Stoff, Ronen and Steinberg, Yael and Amariglio, Ninette and Greenberg, Gahl and Barshack, Iris and Toren, Amos and Yahalom, Ran and Schachter, Jacob and Rechavi, Gideon and Hirschhorn, Ariel and Abebe Campino, Gadi},
title = {Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
volume = {116},
number = {4},
pages = {539--546},
doi = {10.1093/jnci/djad232}
}
EUVIMED